CÔNG TY CỔ PHẦN DƯỢC PHẨM MEDBOLIDE

RESTIVA REPORT – Ho Chi Minh City University of Medicine and Pharmacy Hospital

Tuesday, March 28, 2023, at the Anorectal Department, Ho Chi Minh City University of Medicine and Pharmacy Hospital

CPDP Medbolide Company had a report introducing the intravenous drug product RESTIVA (Diosmin 600mg) to treat hemorrhoids and varicose veins. The report took place with the attendance of more than 30 Doctors and medical staff.

The Company representative presented recommendations and clinical research demonstrating the effectiveness of the drug RESTIVA, a formula containing high levels of Diosmin, pure in micro-purified form (particle size 2 - 20 µm) to help absorption. good, increases bioavailability & gives high clinical effectiveness. Especially with a simple dosage regimen, it helps patients easily comply with treatment. RESTIVA is an effective solution for treating hemorrhoids and chronic venous insufficiency.

After the report, the doctors had many discussions about the use and safety of the drug.

At the end of the report, Medbolide Company sends its thanks and hopes to continue accompanying the Hospital in bringing solutions to improve the quality of life for patients.

Pic 1
Pic 2
Pic 3
Readers comments